EP1455812A4 - Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques - Google Patents

Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques

Info

Publication number
EP1455812A4
EP1455812A4 EP02784651A EP02784651A EP1455812A4 EP 1455812 A4 EP1455812 A4 EP 1455812A4 EP 02784651 A EP02784651 A EP 02784651A EP 02784651 A EP02784651 A EP 02784651A EP 1455812 A4 EP1455812 A4 EP 1455812A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibody
multiple sclerosis
antibody therapy
antagonist anti
sclerosis treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02784651A
Other languages
German (de)
English (en)
Other versions
EP1455812A2 (fr
Inventor
Lorianne K Masuoka
Min F Kwan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1455812A2 publication Critical patent/EP1455812A2/fr
Publication of EP1455812A4 publication Critical patent/EP1455812A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP02784651A 2001-11-26 2002-11-26 Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques Withdrawn EP1455812A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33335501P 2001-11-26 2001-11-26
US333355P 2001-11-26
PCT/US2002/038164 WO2003045978A2 (fr) 2001-11-26 2002-11-26 Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques

Publications (2)

Publication Number Publication Date
EP1455812A2 EP1455812A2 (fr) 2004-09-15
EP1455812A4 true EP1455812A4 (fr) 2006-03-22

Family

ID=23302439

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02784651A Withdrawn EP1455812A4 (fr) 2001-11-26 2002-11-26 Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques

Country Status (5)

Country Link
EP (1) EP1455812A4 (fr)
JP (1) JP2005510570A (fr)
AU (1) AU2002346581A1 (fr)
CA (1) CA2466931A1 (fr)
WO (1) WO2003045978A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ES2400660T3 (es) 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN102585011A (zh) * 2012-02-10 2012-07-18 中国农业大学 一种犬α干扰素衍生物的制备方法与应用
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2021169423A (ja) * 2020-04-15 2021-10-28 洋悦 松川 製剤投与方法
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
WO2025184603A2 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Utilisation d'inhibiteurs de cd40 pour inhiber une réponse immunitaire et permettre une administration et une réadministration d'immunogène
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037870A1 (fr) * 1999-11-25 2001-05-31 Kennedy Rheumatology Inst Traitement de maladies auto-immunes par une proteine liant le cd40 agonistique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037870A1 (fr) * 1999-11-25 2001-05-31 Kennedy Rheumatology Inst Traitement de maladies auto-immunes par une proteine liant le cd40 agonistique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COMABELLA MANUEL ET AL: "Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients", JOURNAL OF NEUROIMMUNOLOGY, vol. 126, no. 1-2, May 2002 (2002-05-01), pages 205 - 212, XP002364117, ISSN: 0165-5728 *
GERRITSE K ET AL: "CD40-CD40 LIGAND INTERACTIONS IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 93, no. 6, 19 March 1996 (1996-03-19), pages 2499 - 2504, XP002013404, ISSN: 0027-8424 *
JEFFERY D R: "Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis.", JOURNAL OF THE NEUROLOGICAL SCIENCES. 1 SEP 2000, vol. 178, no. 1, 1 September 2000 (2000-09-01), pages 2 - 9, XP002220791, ISSN: 0022-510X *
MAURI CLAUDIA ET AL: "Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 6, June 2000 (2000-06-01), pages 673 - 679, XP002157458, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2003045978A3 (fr) 2003-07-31
AU2002346581A1 (en) 2003-06-10
EP1455812A2 (fr) 2004-09-15
CA2466931A1 (fr) 2003-06-05
AU2002346581A8 (en) 2003-06-10
JP2005510570A (ja) 2005-04-21
WO2003045978A2 (fr) 2003-06-05

Similar Documents

Publication Publication Date Title
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
IL158831A0 (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
AU2002346581A8 (en) Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
IL166244A0 (en) Super humanized antibodies
IL200604A0 (en) Human monoclonal antibodies against cd30
IL149701A0 (en) Use of anti-ctla-4 antibodies
EP1482972A4 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
IL156030A0 (en) Humanized antibodies
EP1572131A4 (fr) Therapie fondee sur les anticorps
AU1174702A (en) Humanized anti-lt-beta-r antibodies
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
AU2003277832A8 (en) Humanized tissue factor antibodies
AU2002326991A1 (en) Methods for treating multiple sclerosis
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
AU2002360696A8 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
EP1446416A4 (fr) Anticorps monoclonaux specifiques de tumeur
PL349481A1 (en) Therapeutic preparation against hypoferremia
TW517526U (en) Structure of plate for trapping mouse
GB0121727D0 (en) Monoclonal antibodies
GB0104244D0 (en) Marker for antibody therapy
AU2002211364A1 (en) Human anti-cd40 antibodies
AU2002227175A1 (en) Anti-tenascin monoclonal antibody therapy for lymphoma
HK1072719A (en) Human monoclonal antibodies against cd30
GB0017139D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060208

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091110